Millendo Therapeutics to Present at Jefferies 2019 Healthcare Conference
ANN ARBOR, Mich.--(BUSINESS WIRE)--May 23, 2019--
Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference in New York City on Thursday, June 6, 2019 at 11:00 a.m. ET.
A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit www.millendo.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005640/en/
CONTACT: Millendo Investor Contact:
Stern Investor Relations
firstname.lastname@example.orgMillendo Media Contact:
KEYWORD: UNITED STATES NORTH AMERICA MICHIGAN NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL OTHER HEALTH
SOURCE: Millendo Therapeutics, Inc.
Copyright Business Wire 2019.
PUB: 05/23/2019 04:30 PM/DISC: 05/23/2019 04:30 PM